Figure 3 | Scientific Reports

Figure 3

From: Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer

Figure 3

Comparison of iMethyl-liquid and iMethyl-tissue in predicting ICB efficacy. (a,b) Survival analysis (left) and bootstrap analysis (right) using our (a) breast cancer and (b) lung cancer cohort samples. The survival analysis was performed for the methyl-high and -low group to compare iMethyl-liquid and iMethyl-tissue. For the bootstrap analysis, performance was estimated by 1000 trials of resampling of individual patient samples. In each sampling, the P value from the survival analysis was obtained. The resulting 1000 P values for iMethyl-liquid and iMethyl-tissue were compared by the Wilcoxon signed-rank test (P value of **** < 1 × 10–4). (c) Measurement of iMethyl-liquid and iMethyl-tissue performance in predicting ICB responses by ROC-AUC.

Back to article page